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Cantu´ Syndrome Is Caused by Mutations in ABCC9
Bregje W.M. van Bon,1,14 Christian Gilissen,1,14 Dorothy K. Grange,2 Raoul C.M. Hennekam,3
Hu¨lya Kayserili,4 Hartmut Engels,5 Heiko Reutter,5,6 John R. Ostergaard,7 Eva Morava,8
Konstantinos Tsiakas,9 Bertrand Isidor,10 Martine Le Merrer,11 Metin Eser,4 Nienke Wieskamp,1
Petra de Vries,1 Marloes Steehouwer,1 Joris A. Veltman,1 Stephen P. Robertson,12 Han G. Brunner,1
Bert B.A. de Vries,1,* and Alexander Hoischen1,13
Cantu´ syndrome is a rare disorder characterized by congenital hypertrichosis, neonatal macrosomia, a distinct osteochondrodysplasia,
and cardiomegaly. Using an exome-sequencing approach applied to one proband-parent trio and three unrelated single cases, we
identified heterozygous mutations in ABCC9 in all probands. With the inclusion of the remaining cohort of ten individuals with Cantu´
syndrome, a total of eleven mutations in ABCC9were found. The de novo occurrence in all six simplex cases in our cohort substantiates
the presence of a dominant disease mechanism. All mutations were missense, and several mutations affect Arg1154. This mutation hot
spot lies within the second type 1 transmembrane region of this ATP-binding cassette transporter protein, which may suggest an
activating mutation. ABCC9 encodes the sulfonylurea receptor (SUR) that forms ATP-sensitive potassium channels (KATP channels)
originally shown in cardiac, skeletal, and smooth muscle. Previously, loss-of-function mutations in this gene have been associated
with idiopathic dilated cardiomyopathy type 10 (CMD10). These findings identify the genetic basis of Cantu´ syndrome and suggest
that this is a new member of the potassium channelopathies.Cantu´ syndrome (MIM 239850) is a rare but recognizable
disorder characterized by congenital hypertrichosis,
neonatal macrosomia, a distinct osteochondrodysplasia,
and cardiomegaly. The hypertrichosis leads to thick scalp
hair, which extends onto the forehead, and a general
increase in body hair. In addition,macrocephaly and coarse
facial features, including a broad nasal bridge, epicanthal
folds, a wide mouth, and full lips, can be suggestive of
a storage disorder.1–3 About half of individuals with Cantu´
syndrome are macrosomic and oedematous at birth,
whereas in childhood they usually have amuscular appear-
ance with little subcutaneous fat.3 Although the skeletal
changes reported in amore recent review of ten individuals
were mild,3 a thickened calvarium, narrow thorax, wide
ribs, flattened or ovoid vertebral bodies, coxa valga, osteo-
penia, enlarged medullary canals, and metaphyseal
widening of long bones have been reported previously.1,4
Motor development is usually delayed due to hypotonia,
most individuals have a mild speech delay, and a small
percentagehas learningdifficulties or intellectual disability.
Notably, cardiac manifestations such as patent ductus arte-
riosus, ventricular hypertrophy, pulmonary hypertension,
and pericardial effusions are present in ~80% of cases.1,3
Despite the identification of Cantu´ syndrome as
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autosomal-recessive inheritance was suggested on the
basis of the two affected siblings in the original report
and consanguinity in another family.5,6 However, using
segregation analysis, Robertson et al. showed that Cantu´
syndrome is most likely a dominant disorder.4 In addition,
of the 37 cases of Cantu´ syndrome in the literature, the
majority are simplex cases; also, two known parent-child
transmissions suggest an autosomal-dominant inheritance
pattern.1–12 Except for a distal 1p36 deletion and a
4q26q27 duplication in two individuals with only mild
phenotypic similarities to Cantu´ syndrome, no recurrent
chromosomal aberrations in individuals clinically diag-
nosed with Cantu´ syndrome have been reported that
would allow the identification of the genetic cause.3,7,8
To identify the underlying genetic cause of Cantu´
syndrome, we studied a cohort of 14 individuals, of which
seven were simplex cases and seven were familial cases.
The familial cases consisted of two sisters and their mother
(individuals 2a, 2b, and 2c), a father-daughter pair (indi-
viduals 8a and 8b) and a sibling pair (individuals 9a and
9b). In four families, the parents were consanguineous
(individuals 1, 5, 8b, 9a, and 9b). The clinical details of
these individuals are presented in Table 1, Figure 1A, and
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Table 1. Phenotype of Individuals with Cantu´ Syndrome
Clinical Features
Affected Individuals
1 2a 2b 2c 3 4 5 6 7 8a 8b 9a 9b 10
Gender M F F F M F M F M F M M F M
Mutation (cDNA) 3460C>T 3461G>A 3461G>A 3461G>A 3461G>A 3460C>T 3460C>T 3128G>A 3461G>T 1433C>T 1433C>T - - -
Alteration (protein) Arg1154Trp Arg1154Gln Arg1154Gln Arg1154Gln Arg1154Gln Arg1154Trp Arg1154Trp Cys1043Tyr Arg1154Gln Ala478Val Ala478Val - - -
Inherited de novo inherited inherited de novo de novo de novo de novo de novo inherited
Consanguinity þ - - - - - þ - - - þ þ þ -
Age at evaluation 4 m 16 yrs 10 yrs 39 yrs 8 yrs 21 yrs 3.5 m 4.5 yrs 9.8 yrs 4 m 32 yrs 6 yrs 4 yrs 3 m
Alive - þ þ þ þ þ þ þ þ þ þ þ - þ
Congenital
hypertrichosis
þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Macrosomia at birth þ - þ þ - þ - þ - þ þ - - þ
Macrocephaly þ þ þ þ þ - þ þ þ þ þ þ þ þ
ID* and/or
developmental delay
- - - - þ - þ - - þ - þ þ þ
Facial Features
Coarse face þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Epicanthal folds þ þ þ þ þ þ þ þ þ þ þ þ þ -
Abundant and/or
curly eyelashes
þ þ þ - þ - þ þ þ þ - þ þ þ
Broad and/or
flat nasal bridge
þ þ þ þ þ - þ þ þ þ þ þ þ þ
Small nose and/or
anteverted nostrils
þ þ þ þ þ þ þ þ þ þ - - - þ
Prominent mouth
and/or thick lips
þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Long philtrum þ þ þ þ þ þ þ þ þ þ þ þ þ þ
High and/or
narrow palate
þ þ þ þ - þ þ - - - þ þ þ -
Macroglossy þ þ þ þ - þ þ - - - þ - - -
Anterior open bite - þ þ - - þ - - - - - - -
Gingival hyperplasia þ þ þ þ - þ þ - - þ - - - -
Short neck - - - þ þ - þ þ þ - - þ þ þ
(Continued on next page)
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
0
,
1
0
9
4
–
1
1
0
1
,
Ju
n
e
8
,
2
0
1
2
1
0
9
5
Table 1. Continued
Clinical Features
Affected Individuals
1 2a 2b 2c 3 4 5 6 7 8a 8b 9a 9b 10
Cardiac Features
Structural cardiac
anomalies
þ - - - - þ þ - þ þ - - þ
Pulmory hypertension þ - - - - - - - þ - - - -
Pericardial effusion - þ þ - þ - - - - - - -
Cardiomegaly - þ þ þ þ þ - - þ - þ þ þ þ
Hypertrophic and/or
dilated cardiomyopathy
þ þ þ þ - - - - - - þ þ þ
Radiological Findings
Generalized osteopenia - - - - - þ - þ þ þ þ
Thick calvarium þ þ þ þ - - þ - - þ þ þ þ
Delayed bone age þ - - þ - þ þ þ þ
Enlarged sella turcica,
vertical skull base
- - - - - - þ - - - þ þ þ
Narrow shoulders - - - - - - - - - - - þ þ þ
Narrow thorax - - þ - þ - - - þ - þ þ þ þ
Broad ribs - þ þ þ - - þ þ þ þ - - - þ
Vertebral endplate
irregularities
- - - - þ - - þ - - - þ þ -
Platyspondyly þ þ - þ - þ - - - - - þ þ -
Ovoid vertebral bodies þ - - - - - þ þ - - - þ þ þ
Hypoplastic ischium
and pubic bones
- - - - - - - - - - - þ þ -
Narrow obturator
foramen
- þ - þ - - - -
Erlenmeyer-flask-like
long bones
þ þ þ þ - - þ - þ þ þ -
Bilateral coxa valga - - þ - þ - - - - þ - - þ
Metaphyseal flare
with enl. medul. ca.*
þ þ þ þ þ - þ - þ þ þ þ -
Transverse
metaphyseal bands
- - - - - - - - - - þ - - -
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Table 1. Continued
Clinical Features
Affected Individuals
1 2a 2b 2c 3 4 5 6 7 8a 8b 9a 9b 10
Other Features
Preaxial distal
phalangeal hypoplasia
- - - - - þ - - þ - - -
Short, broad first toe þ - - - - - þ þ þ þ þ þ þ
Umbilical hernia þ - - - - - þ þ - þ þ - - þ
Pyloric stenosis þ - - - - - - - - - - - - þ
Immune deficiency - - - - þ - - þ - þ þ -
Wrinkled and/or
loose skin
þ - - - - - þ - - þ þ þ þ -
Deep palmar creases þ - - - - - þ - - þ þ þ þ -
Finger pads þ - - - - þ þ - - - - - -
Hyperextensibility
interphalangeal joints
þ - þ - - þ þ - þ - þ - - -
Pectus carinatum þ - - - - þ - - - - - - - -
Genital anomalies þ - - - - - þ - - þ - - -
Scoliosis þ þ þ þ - - - - - - - - - -
Lymphedema - þ þ þ - þ - - - - þ þ þ -
Increased tendency for
upper GI* bleeding
- - - - - - - - - - - - -
Renal anomalies - - - - - - - þ - - -
Previously published yes1 yes1 yes 1 yes12
RefSeq accession number NM_020297.2 was used in naming mutations. Features that were not available were left blank. Adapted from Engels et al. 2002.12
*Abbreviations: enl. medul. ca., enlarged medullary canal; F, female; GI ¼ gastrointestinal; ID, intellectual disability; m, months; M, male; yrs, years.
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Figure 1. Mutations in ABCC9 Cause Cantu´ Syndorme
(A) Portrait photographs of Cantu´ syndrome individuals with ABCC9mutations, identified by exome sequencing or Sanger sequencing.
Note the coarse facial appearance, including a broad nasal bridge, a short nose, a long philtrum, a wide mouth, and full lips.
(B) De novo ABCC9 mutation g.21995261G>A (c.3460C>T; p. Arg1154Trp) identified by exome sequencing of an affected individual
and his parents. The upper panel shows the next generation sequencing reads of the child (individual 1) followed by the reads of the
father (middle) and mother (bottom).
(C) Sanger validation in the same trio; Sanger traces of the child (individual 1, top), father (middle), and mother (bottom). The point
mutation (g.21995261G>A; c.3460C>T) is marked with a red arrow.
(D) Schematic overview of SUR2, with Cantu´ syndrome-causing mutations depicted by the arrow. Abbreviations: ABC, ATP-binding
cassette transporter domain (red); TMD, ABC transmembrane domain type-1 (blue).
(E) Amino-acid conservation of the mutation hot spot p.Arg1154 for multiple species (human, mouse, dog, chicken, zebrafish); the
highly conserved arginine is depicted in red.sequenced individuals were selected from the cohort as
those most resembling the phenotype initially outlined
by Cantu´ et al.5
Initially, we applied an exome-sequencing approach to
data from three individuals using a SOLiD v4 sequencing
instrument and Agilent’s SureSelect v1 (38 Mb) exome-
enrichment kit. Detected variants were prioritized as
described previously (Table S1).13,14 Only one gene
(RP1L1 [MIM 608581]) harbored variants in all three
individuals, but these were not validated by Sanger
sequencing. Therefore, we performed additional exome
sequencing on a simplex case (individual 1) and his
parents (Table S2). De novo analysis (as described in Vissers
et al.15) resulted in 15 potential de novo mutations in
15 candidate genes (Figures 1B and 1C and Table S2).
Systematic validation through Sanger sequencing of all
15 candidates showed that only a mutation in ABCC9
(c.3460C>T) could be validated in the affected indi-
vidual.15 Furthermore, of these 15 candidate genes,
private, nonsynonymous variants could only be identified
in ABCC9 (MIM 601439), in two of the three initially
sequenced individuals (individuals 3 and 4; c.3461G>A).1098 The American Journal of Human Genetics 90, 1094–1101, JuneVisual inspection of the exome-sequencing data of the
third individual (individual 2a, c.3460C>T) identified an
additional potential mutation in ABCC9 at very low
sequence coverage. Notably, all mutations resided within
exon 27 of ABCC9.
In the remaining cohort of ten individuals with Cantu´
syndrome, five additional missense mutations were found
in ABCC9 through Sanger sequencing (NM_020297.2;
Table S3). Thus, in total, 11/14 cases had an ABCC9 muta-
tion. Interestingly, eight mutations occured in a mutation
hot spot, affecting the Arg1154 residue in exon 27, which
affected the second type 1 transmembrane region (TMD2:
transmembrane domain 2) of the protein encoded by
ABCC9, sulfonylurea receptor (SUR2) (Figure 1D). All other
mutations (c.3128G>A [p.Cys1043Tyr] and c.1433C>T
[p.Ala478Val]) also affected either TMD1 or TMD2.
All mutations but one (that found in individuals 8a
and b) have been predicted to be possibly or probably
damaging by multiple in silico prediction programs. The
base-pair conservation (measured by phyloP) was relatively
high, whereas the Arg1154 residue was conserved up to
zebrafish (Figure 1E). Importantly, in all six simplex cases,8, 2012
the mutations occurred de novo (Figure S1). Furthermore,
none of the mutations have been identified in any of the
over 5,000 publicly available exomes (Exome Variant
Server, NHLBI Exome Sequencing Project [ESP], Seattle).
All procedures were in accordance with the ethical stan-
dards of the responsible committee on human experimen-
tation (institutional and national), and proper informed
consent was obtained.
ABCC9 is a member of the ATP-binding cassette
subfamily C, also known as the CFTR/MDR (cystic fibrosis
transmembrane conductance regulator and multidrug
resistance protein) family, and encodes the channel
regulator SUR2, which contains TMD1 and TMD2, an
N-terminal domain (TMD0), and two nucleotide-binding
folds (NBF1 and NBF2), comprising Walker A and Walker
B nucleotide-binding motifs and other conserved
sequences.16,17 Together with a member of the Kir channel
family, SUR2 forms ATP-sensitive potassium channels
(KATP channels) consisting of four SUR2 subunits and
four pore-forming Kir subunits.17 Alternative RNA splicing
of the terminal exon of ABCC9 produces two SUR2 iso-
forms: SUR2A, predominantly expressed in cardiac and
skeletal muscle cells, and SUR2B in smooth muscle.18
Interestingly, the genes for Kir6.1 (KCNJ8 [MIM 600935])
and SUR2 are located in a cluster of genes on chromosome
12p12.1, suggesting coregulation at the gene level.19 A
similar situation is observed for Kir6.2 (KCNJ11 [MIM
600937]) and SUR1 (ABCC8 [MIM 600509]), which are
also located in a cluster of genes but on chromosome
11p15.1. This provides evidence that these regions were
produced in an ancient duplication event, which is in
line with its preservation from zebrafish to human
(Figure 1E).20 Whereas the chromosome 12 cluster-
encoded KATP channel functions primarily in heart,
skeletal, and smooth muscle, the chromosome 11 cluster-
encoded KATP channel shows a predominant role in the
neuroendocrine system, and mutations in these genes
may lead to hyperinsulinemic hypoglycemia and neonatal
diabetes.18
KATP channels open and close in response to intracellular
changes in the ADP/ATP ratio, thereby linking the meta-
bolic state of the cell to its membrane potential.17,18,21
Inhibition of KATP channel activity causes membrane
depolarization and thereby activation of voltage-depen-
dent Ca2þ channels, leading to Ca2þ influx and a rise in
intracellular [Ca2þ].19
Correct maintenance of calcium handling is essential
for the normal functioning of the heart, and dysfunctional
myocellular calcium homeostasis contributes to the
pathogenesis of dilated cardiomyopathy (CMD10 [MIM
608569]).22–24 In Sur2/ mice, KATP channel activity is
essentially absent, and these animals show hypertension,
coronary artery vasospasm, and sudden cardiac death.
Previously, mutations in exon 38 of ABCC9, which
encodes the C terminus of SUR2A, have been reported in
two individuals with idiopathic CMD10.25 One of these
mutations was later reported as a variant of unknownThe Americfrequency in dbSNP (rs72559751). Interestingly, the
mutations described for CMD10 affect an exon that is
only transcribed in the isoform SUR2A, which shows
high cardiac muscle expression, whereas this mutation
does not affect the SUR2B isoform, which is expressed
predominantly in vascular smooth muscle. This may
explain why the phenotype remains restricted to the heart,
even though the frameshift mutation affects a gene which
might have a more general function, as implicated by
the various clinical problems in individuals with Cantu´
syndrome.
The individuals with Cantu´ syndrome that have a causa-
tive mutation in ABCC9 are clinically as severely affected
as those for whom no mutation could be detected. Further
studies are required to determine whether this reflects
genetic heterogeneity.
Remarkably, in 2006, Grange et al. noted the overlap-
ping phenotype in individuals with Cantu´ syndrome
and individuals treated with Minoxidil, a KATP channel
opener.1,26 This drug is used for treatment of hypertension
as well as baldness, and treated individuals showed a
similarly increased body-hair pattern and pericardial
effusions.27 Other reported effects of Minoxidil include
increased elastin expression in smooth muscle cells and
edema.28 Minoxidil acts as a KATP channel agonist to
increase potassium permeability, resulting in a decrease
in cytoplasmic [Ca2þ] and subsequent smooth muscle
relaxation.29,30 This reduced vascular resistance and higher
cardiac output may result in increased cardiac muscle
mass. Because of the clinical overlap between the effects
of Minoxidil treatment and Cantu´ syndrome, one could
speculate that they have the same underlying mechanism
for opening the KATP channel.
None of our individuals had deletions or protein-
truncating mutations, and the phenotypes of four individ-
uals, 139, 262714, 263616, and 255953 as reported in
DECIPHER (Database of Chromosomal Imbalance and
Phenotype in Humans Using Ensembl Resources), with
overlapping deletions and a duplication, respectively, do
not resemble Cantu´ syndrome. These results support the
role of activating mutations as an underlying mechanism
in Cantu´ syndrome. An indirect proof that the Cantu´
syndrome-causing mutations are activating mutations
comes from homologous mutations identified in ABCC8
(which encodes SUR1) that are a common cause of
neonatal diabetes.31,32 The authors of Babenko et al.
showed an activating effect of ABCC8 mutations, one of
which affected the amino acid homologous to our identi-
fied hot spot (Arg1154).31 They concluded that mutations
overactivate KATP channels, and that the enhanced stimu-
latory action of the mutant receptor is sufficient to keep
KATP channels open, even at an elevated ratio of ATP to
ADP.31 Interestingly, the majority of these individuals are
treated by sulphonylurea tablets,31,33 a drug that binds to
the SUR1 subunit to cause channel closure independently
of ATP.33 Depending on the exact functional consequence
of the mutations, the determination of which will requirean Journal of Human Genetics 90, 1094–1101, June 8, 2012 1099
further studies, one could consider therapeutic options for
individuals with Cantu´ syndrome using a similar strategy.
In summary, we identified the underlying genetic cause
of Cantu´ syndrome, mutations in ABCC9, and propose
that this syndrome be added to the list of potassium
channelopathies with potential therapeutic options.Supplemental Data
Supplemental Data include one figure and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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